Technology doesn't transform you by existing.
Between what becomes possible and what your company can actually do sits a gap, and that gap is where most transformation dies. The capacity to close it, over and over as the technology shifts underneath you, has a name.
Translational intelligence
The institutional capacity to convert emerging technological capability into durable scientific, operational, and strategic advantage.
The problem it names
A frontier model behind a login is not transformation. A thousand licenses are not transformation. A backlog of three hundred pilots is not transformation. Those are inputs. You can buy every one of them and still be the same company you were last year, only with a bigger software bill.
Possibility and consequence are not the same thing. Something becomes technically possible in a lab or a demo. Turning it into how a real institution decides, works, and competes is a separate act, and it is the hard one. Translational intelligence is the name for being good at that second act, on purpose, again and again.
The chain, link by link
Capability asks what has become possible. Permission asks whether your organization may responsibly act, with which data and under whose accountability. Behavior asks whether people actually reach for the new capability when the work calls for it. Workflow asks whether you redesigned the work around it or just bolted it on. Decision asks whether you now decide better, or sooner. Learning asks whether each use makes the institution smarter for the next one. And Advantage asks the only question that finally matters: did any of it produce durable value?
Most organizations break at Behavior and Workflow, not at Capability. They have the tools. They do not have the habits, or the redesigned work.
So they pour money into the first link of the chain and wonder why nothing moves at the last. Find the link where your company actually breaks, and fix that one, not the one that is easiest to buy.
What it is, and what it is not
It is not owning the best model. Models change every few months, and whichever one is ahead today will not be ahead for long. Translational intelligence is the capacity to keep turning whatever new capability arrives into new institutional capability, whoever built the model this quarter.
Here is how the pieces fit. Translational intelligence is the capacity. Permission, People, and Programs is the system that creates it. The AI Product Partner is the human who sits where capability meets the work and turns one into the other. And the AI-native biotech is the institution you get when all of it runs. One capacity, one system, one role, one destination.
Why biotech, most of all
Biotech is where this matters most, and where the wrong answer costs the most. The work is knowledge work under real constraint: scientific judgment, regulatory accountability, patient safety, decisions that take years to prove right or wrong. So the value of translation is rarely just hours saved. It shows up in cycle time, in the quality and timing of a decision, in whether a scientist spends scarce expertise on the thing only they can do, in the probability a program succeeds at all. Move a good decision earlier, with better evidence, and you have an advantage no license agreement confers.
It is slower than buying something.
You cannot purchase translational intelligence, install it, and check the box. It gets built in the least glamorous places: policy people can follow, training embedded in real work, workflows taken apart and rebuilt, adoption owned long after launch. It is mostly human work, and human work resists a timeline. There is also no final form to reach. The technology keeps changing, so the capacity is never finished. If that sounds like a burden, it is also the point: the durable advantage is precisely the part that never settles.
Walk your own chain.
Take the chain, from Capability to Advantage, and walk your organization along it until you find the link that breaks. It is usually not the one you are spending on. Fix the real link, not the visible one, because that is where transformation begins.
Then read The Biotech of Tomorrow for the argument that this is the whole game.